Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Net Asset Value(s)

16 Jan 2023 07:00

RNS Number : 7206M
RTW Venture Fund Limited
16 January 2023
 

LEI: 549300Q7EXQQH6KF7Z84

16 January 2023

RTW Venture Fund Limited

Net Asset Value

RTW Venture Fund Limited (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 31 December 2022 (the "NAV") was US$326 million, or US$1.54 per ordinary share, an increase of 9.4% from the previous month.

As of 31 December 2022, 24.6% of the total NAV was invested in privately held core portfolio companies and 46.3% of the total NAV was invested in public core portfolio companies, most of which were initiated as private investments. 29.8% was invested in other liquid public positions (which mirror holdings in RTW Investments, LP private funds) in lieu of holding cash for future core investments.

For Further Information:

RTW Investments, LP

+44 (0) 77 1741 7711

Woody Stileman, Managing Director

 

 

 

Buchanan

+44 (0)20 7466 5107

Charles Ryland

 

Henry Wilson

 

George Beale

 

 

 

J.P. Morgan Cazenove

+44 (0)20 7742 4000

William Simmonds

 

Jérémie Birnbaum

 

James Bouverat (Sales)

 

 

BofA Securities

+44 (0) 20 7628 1000

Edward Peel

 

Kieran Millar

 

 

Elysium Fund Management Limited

+44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

 

Sadie Morrison, Managing Director

 

 

 

Morgan Stanley Fund Services USA LLC

+1 (914) 225 8885

 

 

Note:

1.

The NAV is determined by the Company's investment manager, RTW Investments, LP, in accordance with the Company's accounting policies. Investments by the Company in privately-held companies ("Private Portfolio Companies") have been valued at fair market value, taking into account the valuation prepared by Alvarez & Marsal Valuation Services LLC and the nature, facts and circumstances of the Private Portfolio Companies. Investments by the Company in companies listed on a public stock exchange (the "Public Portfolio Companies") have each been valued by reference to their market capitalisation as at close of business on 31 December 2022. The Company applies a valuation discount to its investments in Public Portfolio Companies that are subject to post-IPO lock-up provisions.

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVGPUWUGUPWGCW
Date   Source Headline
13th Feb 20267:00 amRNSMonthly Valuation Update and Factsheet
23rd Jan 20267:00 amRNSCorxel completes $287 million Series D-1 financing
22nd Jan 202610:00 amRNSDirector/PDMR Shareholding
21st Jan 20267:00 amRNSGSK to acquire RAPT Therapeutics
16th Jan 20267:00 amRNSBoston Scientific to acquire Penumbra
15th Jan 20267:00 amRNSMonthly Valuation Update and Factsheet
12th Jan 20267:00 amRNSAktis announces $318 million IPO
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
18th Dec 20257:00 amRNSNew investment in Yarrow Bioscience
12th Dec 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSInclusion in FTSE 250 Index
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20256:00 pmRNSSpectris
1st Dec 20257:00 amRNSTotal Voting Rights
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20252:30 pmRNSTransaction in Own Shares
25th Nov 202512:00 pmRNSRetail Investor Webinar
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSMonthly Valuation Update and Factsheet
7th Nov 20257:00 amRNSEvommune announces $150 million IPO
5th Nov 202510:00 amRNSHolding(s) in Company
3rd Nov 20259:33 amRNSTotal Voting Rights
31st Oct 20257:00 amRNSRoyalty Funding Agreement with Savara Inc.
29th Oct 20257:00 amRNSTransaction in Own Shares
27th Oct 20257:00 amRNSNovartis to acquire Avidity Biosciences
20th Oct 20257:00 amRNSCapital Allocation Plan based on M&A successes
15th Oct 20257:00 amRNSKailera Therapeutics announces Series B financing
14th Oct 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Oct 20257:00 amRNSNovo Nordisk to acquire Akero Therapeutics
1st Oct 20257:00 amRNSTotal Voting Rights
30th Sep 20257:01 amRNSTransaction in Own Shares
30th Sep 20257:00 amRNSGenmab to acquire Merus
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20257:01 amRNSTransaction in Own Shares
23rd Sep 20257:00 amRNSBiogen to acquire Alcyone Therapeutics
15th Sep 20257:00 amRNSMonthly Valuation Update and Factsheet
11th Sep 20257:00 amRNSHalf-year Report
5th Sep 20257:00 amRNSInclusion in FTSE All-Share Index
1st Sep 20257:00 amRNSTotal Voting Rights
22nd Aug 20257:00 amRNSTransaction in Own Shares
19th Aug 20257:01 amRNSNotice of Interim Results
19th Aug 20257:00 amRNSStrategic Funding Agreement with Aquestive
15th Aug 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.